• Local excision with chemoradiation therapy could be one of the alternative therapeutic strategies for the organ preservation and a cure of cancer. (pfmjournal.org)
  • Neoadjuvant chemoradiation therapy (CRT), radical resection based on total mesorectal excision (TME), and adjuvant chemotherapy have improved the survival and recurrence rates of locally advanced rectal cancer [ 2 , 3 ]. (pfmjournal.org)
  • Advanced rectal cancers were traditionally treated with neoadjuvant chemoradiation therapy (nCRT) followed by total mesorectal excision (TME) and postoperative adjuvant chemotherapy [ 1 , 2 ]. (coloproctol.org)
  • Initial studies with 5-fluorouracil and leucovorin followed by the MOSAIC study which incorporated oxaliplatin have led to the current use of the FOLFOX (leucovorin, 5-fluorouracil and oxaliplatin) regimen. (wikidot.com)
  • in both cases of chemotherapy alone, the majority of patients (91%) received oxaliplatin-based protocols (FOLFOX/XELOX/CAPOX). (unict.it)
  • The latest Chinese guidelines recommend atezolizumab plus bevacizumab, suntilimab plus a bevacizumab analog, lenvatinib, sorafenib, donafenib, and FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy as first-line treatment without priority. (e-cmh.org)
  • Patients in arm 2 received concurrent chemotherapy consisting of five doses of oxaliplatin (50 mg/m2 IV weekly) and capecitabine (1600 mg/m2/d orally Monday through Friday during radiation therapy). (appliedradiationoncology.com)
  • In the present study, the clinicopathological features of 173 patients with stage III CRC who underwent radical resection and adjuvant chemotherapy with the fluoropyrimidine/folinic acid, and oxaliplatin (FOLFOX) regimen, and their prognostic values of EGFR expression were retrospectively analyzed. (oncotarget.com)
  • Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. (helsedirektoratet.no)
  • RTOG 0247 was a randomized, Phase II multicenter trial of patients with locally advanced (T3 and T4) rectal cancer treated with neoadjuvant chemoradiation from March 2004 to February 2007. (appliedradiationoncology.com)
  • TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. (inclinicaltrials.com)
  • Studies of patients with mismatch repair deficiency has shown that those with intact mismatch repair respond better to 5-fluorouracil based chemotherapy, and patients with MMR deficiency may do worse with systemic therapy. (wikidot.com)
  • Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. (canceropole-est.org)
  • She said that the reduction in long-term radiotherapy-related toxicities make the novel regimen a good choice, although the decision should be made with the patient. (medscape.com)
  • The primary endpoint analysis of RTOG 0247 examined the pathologic complete remission (pCR) rates of two concurrent neoadjuvant chemotherapy regimens to determine which regimen should be studied further. (appliedradiationoncology.com)
  • Patients were randomized to two chemotherapy treatment arms concurrent to their radiation therapy: Patients in arm 1 received concurrent chemotherapy consisting of four doses of irinotecan (50 mg/m2 IV weekly) and capecitabine (1200 mg/m2/d orally Monday through Friday during radiation therapy). (appliedradiationoncology.com)
  • The initial FOLFOX study (MOSAIC) demonstrated equivalent survival in patients who received FOLFOX vs 5-FU based regimens. (wikidot.com)
  • For chemotherapy, two-drug cytotoxic regimens that include a platinum agent are generally preferred for first-line therapy. (medscape.com)
  • Our new analysis of RTOG 0247 provides us with favorable efficacy results of two preoperative chemotherapy regimens used in conjunction with radiation therapy protocols," said Neal J. Meropol, MD, co-author of the study, and the Dr. Lester E. Coleman Jr., Professor of Cancer Research and Therapeutics and chief of the Division of Hematology and Oncology at University Hospitals Case Medical Center and Case Western Reserve University in Cleveland. (appliedradiationoncology.com)
  • Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. (canceropole-est.org)
  • Adjuvant therapies are used when there is nodal involvement (chemotherapy) or invasion of adjacent structures (radiotherapy). (wikidot.com)
  • Adjuvant therapies are therefore considered for patients with disease stage greater than I. (wikidot.com)
  • This has shaped the development of adjuvant therapies, with chemotherapy the main focus of interest for colon cancer. (wikidot.com)
  • Preclinical success has led to a profusion of clinical trials on LB100 adjuvant therapies, including a phase I trial in extensive-stage small-cell lung cancer, a phase I/II trial in myelodysplastic syndrome, a phase II trial in recurrent glioblastoma, and a completed phase I trial assessing the safety of LB100 and docetaxel in various relapsed solid tumors. (cancerbiomed.org)
  • Treatments used for colorectal cancer may include some combination of surgery, radiation therapy, chemotherapy, and targeted therapy. (wikipedia.org)
  • The use of neoadjuvant radiation therapy and chemotherapy in the treatment of locally advanced rectal adenocarcinoma has been shown to reduce disease recurrence when combined with surgery and adjuvant chemotherapy. (biomedcentral.com)
  • To the best of our knowledge, this is the first such complication from radiation therapy reported in a patient with colorectal cancer. (biomedcentral.com)
  • The disproportionate severity of our patient's myopathy relative to the dose of radiation used also makes this case unique among reports of neuromuscular complications from radiation therapy. (biomedcentral.com)
  • He underwent neoadjuvant concurrent pelvic radiation therapy and capecitabine-based chemotherapy, followed by abdominoperineal resection and post-operative FOLFOX chemotherapy. (biomedcentral.com)
  • Radiation recall is a phenomenon whereby previously irradiated tissue becomes vulnerable to toxicity by subsequent systemic therapy and is rarely associated with myopathies. (biomedcentral.com)
  • Radiation recall should be considered a potential complication of neoadjuvant radiation therapy for rectal cancer, and for ongoing research into the optimization of treatment for these patients. (biomedcentral.com)
  • Treatment begins with a course of pre-operative ( neo adjuvant) chemotherapy and radiation therapy (CRT), followed by surgical resection of the tumour with sphincter-sparing TME or non-sphincter-sparing surgery, most commonly either a low anterior resection (LAR) or abdominoperineal resection (APR), and post-operative (adjuvant) chemotherapy. (biomedcentral.com)
  • Radiation therapy is often given with chemotherapy. (medscape.com)
  • External beam radiation therapy (EBRT) is used. (medscape.com)
  • Aim To conduct a survey among Sicilian centers of radiation oncology belonging to Associazione Italiana di Radioterapia ed Oncologia Clinica (AIRO), to record the different methods of integration of radio-chemotherapy both in neoadjuvant and adjuvant settings, to evaluate surgical procedures in relation to the sphincter preservation and to report the different toxicity profiles of the treatment strategies. (unict.it)
  • Internal radiotherapy that uses a source of radiation inside the body for a short period of time. (bowelcanceruk.org.uk)
  • First, in many parts of the world, radiation therapy is not readily accessible. (medscape.com)
  • This study is a secondary endpoint analysis of Radiation Therapy Oncology Group (RTOG) 0247, originally published in 2012[1], to evaluate long-term survival outcomes and patterns of failure. (appliedradiationoncology.com)
  • All patients received preoperative pelvic radiation therapy of 50.4 Gy over five-and-a-half weeks, with 45 Gy delivered in 25 fractions (1.8 Gy per fraction, five fractions per week for five weeks) and a boost of 5.4 Gy in three fractions. (appliedradiationoncology.com)
  • All patients in each arm had surgery four to six weeks after completion of radiation therapy, and all patients in both arms had postoperative chemotherapy of FOLFOX four to six weeks after surgery. (appliedradiationoncology.com)
  • Patient evaluations occurred weekly during concurrent chemotherapy and radiation therapy, before surgery and before each cycle of postoperative chemotherapy. (appliedradiationoncology.com)
  • Finally, neoadjuvant therapy consisting of Capecitabine plus radiation therapy, for locally advanced rectal cancer was analysed. (wjgnet.com)
  • A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. (helsedirektoratet.no)
  • The RAPIDO trial [ 8 ] compared the short-course radiation therapy followed by consolidation chemotherapy with standard long-course nCRT. (coloproctol.org)
  • Long-course radiotherapy (RT) with concurrent systemic chemotherapy followed by total mesorectal excision after 6-10 weeks is a standard treatment for patients with locally advanced mid-to-low rectal cancer [ 1 ]. (kjco.org)
  • the patients who have complete remission from the neoadjuvant chemotherapy have a significant improvement on the survival rate. (abdominalkey.com)
  • Mismatch repair-deficient tumors do not respond well to chemotherapy applied in the neoadjuvant, adjuvant, or metastatic settings. (cancer.gov)
  • The neoadjuvant chemotherapy is a systematic chemotherapy applied for the treatment of cancer, before radical surgery or radiotherapy, also known as preoperative chemotherapy. (abdominalkey.com)
  • This combination of chemotherapy and radiotherapy has a special role in tumor down staging and in sphincter preservation for lower rectal tumors. (wjgnet.com)
  • While patients with microsatellite instable, metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. (omicsdi.org)
  • To discuss current and emerging therapy options for esophageal cancer, ONCOLOGY spoke with Geoffrey Y. Ku, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who specializes in the treatment of malignancies of the gastrointestinal tract, including esophageal tumors. (cancernetwork.com)
  • PURPOSE: Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. (bvsalud.org)
  • The requested data concerned the type of integrated treatment (neoadjuvant vs adjuvant vs radical), combination with chemotherapy (induction, concomitant, adjuvant), type of surgical intervention (sphincter-saving vs abdomino-perineal resection), disease stage, schedule and radiotherapy technique adopted, as well as toxicity detected over the treatment period. (unict.it)
  • The overall rate of sphincter-saving surgery (anterior resection) was 72%, but the contribution of neoadjuvant treatment allowed to reach a rate of 83% in this subgroup (against 65% found in the subgroup of patients treated in adjuvant phase). (unict.it)
  • Traditional radiotherapy schedule (45-50 Gy in 25-28 fractions) was used in 90% of patients, of which an intensified treatment in neoadjuvant phase (45 Gy + boost of 9-10 Gy) was used in 11% of patients. (unict.it)
  • 20 - 25 ] A major pooled analysis evaluating the impact of T and N stage and treatment on survival and relapse in patients with rectal cancer who are treated with adjuvant therapy confirmed these findings. (cancer.gov)
  • Considering the aggressive nature of HBV-associated HCC, multimodal and high-intensity strategies like the addition of immunotherapy-based systemic treatment to local therapies, including resection, ablation, and intra-arterial therapies, have been adopted in real-life practices in China. (e-cmh.org)
  • Preoperative (chemo)radiotherapy has been widely used as an effective treatment for locally advanced rectal cancer (LARC), leading to a significant reduction in pelvic recurrence rates. (mysciencework.com)
  • Our sample included about 27,000 patients who were required to have started their treatment, their first line of therapy, between March 2020 and November 2021 with follow up through March 2022. (ascopost.com)
  • Chemotherapy and radiotherapy are associated with side effects which reduce tolerance to treatment and likelihood of tumour response. (cambridge.org)
  • With regard to adjuvant and neoadjuvant treatment of esophageal and gastroesophageal adenocarcinomas, we very much continue to administer preoperative chemoradiation. (cancernetwork.com)
  • A new treatment strategy named total neoadjuvant therapy (TNT), consists of chemotherapy given before or after the CRT to control micrometastatic disease earlier and improve compliance with chemotherapy. (coloproctol.org)
  • Results of the phase I/II RAPPORT trial demonstrate the feasibility of stereotactic ablative body radiotherapy followed by pembrolizumab as a treatment modality for patients with oligometastatic clear cell renal cell carcinoma. (congressupdateoncology.be)
  • Stereotactic ablative body radiotherapy (SABR) is a treatment option for patients with oligometastatic clear cell renal cell carcinoma (ccRCC), however, patients often experience distant progression. (congressupdateoncology.be)
  • Combining some of these neoadjuvant approaches with standard-of-care chemotherapy or radiotherapy appears to "sensitize" tumor cells to treatment. (cancerbiomed.org)
  • 50%), better clinical models and pipelines for targeted therapies are urgently required. (hrb.ie)
  • Less certainty exists on the role of nutrition therapy in improving cancer patients' body composition and clinical outcome. (cambridge.org)
  • Patients who had non-elective surgery, pre-operative radiotherapy and chemotherapy and showed clinical evidence of infection or other inflammatory conditions were excluded from the study. (scirp.org)
  • The aim of this study was to evaluate the clinical outcomes of short-course radiotherapy (RT) followed by systemic chemotherapy for patients with rectal cancer with mesorectal fascia (MRF) involvement and unresectable distant metastases. (kjco.org)
  • These dramatic changes reflected the results of 2 prospective randomized clinical trials, i.e., the RAPIDO (Rectal Cancer and Preoperative Induction Therapy Followed by Dedicated Operation) trial [ 8 ] and PRODIGE (Partenariat de Recherche en Oncologie Digestive) 23 trial [ 9 ] in 2021. (coloproctol.org)
  • METHODS: We conducted a multi-institutional prospective imaging substudy within NRG-GI002 (ClinicalTrials.gov identifier: NCT02921256) examining the ability of MR-based imaging to predict pathologic complete response (pCR) and correlate MR-TRG with the pathologic neoadjuvant response score (NAR). (bvsalud.org)
  • Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone? (wjgnet.com)
  • Khan K, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone? (wjgnet.com)
  • Modifying the delivery of systemic chemotherapy to improve patients' survival is another progress in colorectal cancer management, known as total neoadjuvant therapy (TNT). (coloproctol.org)
  • This study establishes preoperative therapy with FOLFOX and only selective use of chemoradiation for patients with locally advanced rectal cancer," commented principal investigator Deborah Schrag, MD, MPH, gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center, New York City. (medscape.com)
  • METHODS: Patients with advanced cancer undergoing tumor-only genetic sequencing in the National Cancer Institute Molecular Analysis for Therapy Choice (MATCH) trial were randomized to a web-based genetic education intervention or usual care. (bvsalud.org)
  • Patients have 5 year survival of up to 95% without additional therapy. (wikidot.com)
  • Conclusion The present survey shows that in the Sicily region integrated therapies for rectal cancer have allowed a neoadjuvant approach in the majority of patients, thus resulting in a greater use of sphincter conservative surgery. (unict.it)
  • CHICAGO - Many patients with locally advanced rectal cancer who do not have high-risk disease can skip radiotherapy to the pelvic area, and instead be treated with chemotherapy alone and then surgery, say researchers reporting results from the PROSPECT trial. (medscape.com)
  • She said the trial was "practice changing, and it aligns incredibly well with the theme at this year's annual meeting around de-escalation of therapy and partnering with patients. (medscape.com)
  • Marijnen also pointed out that the definition of "locally advanced" in rectal cancer varies by region, and that in Europe many of the patients in the current trial would be defined as early and intermediate stage, and so would not qualify for neoadjuvant therapy. (medscape.com)
  • Regorafenib, apatinib, camrelizumab, and tislelizumab have been added as second-line systemic therapies for patients who progressed on sorafenib. (e-cmh.org)
  • Endocrine therapy is frequently administered in patients with hormone dependent (HR+) metastatic endometrial cancer. (mysciencework.com)
  • Newly diagnosed cancer patients are frequently found suffering from a metastatic disease, which poses additional challenges to the delivery of effective therapies. (cambridge.org)
  • Identifying preventable factors of reduced response to therapy would translate into better care of cancer patients. (cambridge.org)
  • When part of early palliative care, nutrition therapy improves cancer patients' quality of life and may prolong survival at a fraction of the costs of developing new drugs. (cambridge.org)
  • Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. (helsedirektoratet.no)
  • Tailoring therapy based on different characteristics for patients with stage II gastric cancer may produce better outcomes. (springeropen.com)
  • The preoperative NLR-PLR score is a useful predictor of postoperative survival in the patients with stage I-II gastric cancer and may help identify high-risk patients for rational therapy and timely follow-up. (biomedcentral.com)
  • CONCLUSION:These results indicate that the introduction of cabazitaxel for Japanese mCRPC patients could result in oncological outcomes without any association with patient's age and the profiles of previous docetaxel therapy. (shengsci.com)
  • This single arm trial enrolled 30 oligometastatic ccRCC patients to receive SABR to all metastatic sites (20Gy single dose, or 30Gy across 10 fractions of conventional radiotherapy [CRT] if SABR was not feasible) followed by pembrolizumab (200 mg every 3 weeks) for 8 cycles. (congressupdateoncology.be)
  • More than three quarters (77%) of patients did not receive prior therapy. (congressupdateoncology.be)
  • Univariate and multivariate analyses revealed that there were no significant correlation of patient age (p = 0.537), the response to prior docetaxel therapy (p = 0.339) or cycles of docetaxel therapy (p = 0.379) with shorter OS. (shengsci.com)
  • However, locally advanced T3-4 disease penetrating through the wall of the rectum (stage II) or involving local lymph nodes (stage III) requires aggressive multimodal therapy. (biomedcentral.com)
  • Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivie. (trialstracker.net)
  • Our goal is to develop and use cutting edge systems biology approaches to elucidate molecular signatures of complex immune diseases, understand the mechanisms of disease, and identify the right therapy for the right patient. (benaroyaresearch.org)
  • For esophageal squamous cell cancer, we consider standard therapy to be definitive chemoradiation with observation. (cancernetwork.com)
  • In this report, we present a patient who experienced a rare complication following neoadjuvant CRT, surgery, and adjuvant chemotherapy for locally invasive rectal adenocarcinoma. (biomedcentral.com)
  • Transarterially administered gene therapy for primary and secondary liver malignancies. (aetna.com)
  • Marijnen concluded that that future aims should be to increase the complete response rate above the current 25%, and to ask whether, in the population studied in this trial, neoadjuvant therapy "is needed at all. (medscape.com)
  • Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours: The RAPPORT trial. (congressupdateoncology.be)
  • Second-line and subsequent therapy may involve single agents (eg, taxanes) or molecular therapy, such as ramucirumab to target vascular endothelial growth factor (VEGF) receptor or trastuzumab for metastatic adenocarcinoma that overexpresses HER2. (medscape.com)
  • However, newer options such as targeted therapy, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and immunotherapy may have the potential to alter the standard of care. (cancernetwork.com)
  • Systemic therapies adopted in real-life practice are sophisticated with various combination modalities and different sequences. (e-cmh.org)
  • Five months post-completion of pelvic radiotherapy and 2 months after the completion of adjuvant chemotherapy, he presented with bilateral weakness of the iliopsoas muscles and severe pain radiating to the groin. (biomedcentral.com)